These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17285224)

  • 1. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis.
    Morozzi G; Fabbroni M; Bellisai F; Cucini S; Simpatico A; Galeazzi M
    Clin Rheumatol; 2007 Aug; 26(8):1335-8. PubMed ID: 17285224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
    Kawashiri SY; Kawakami A; Ueki Y; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Origuchi T; Ida H; Eguchi K
    Joint Bone Spine; 2010 Oct; 77(5):418-20. PubMed ID: 20864374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study.
    Gilliam BE; Chauhan AK; Low JM; Moore TL
    Clin Exp Rheumatol; 2008; 26(3):492-7. PubMed ID: 18578976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis.
    Skoumal M; Kolarz G; Klingler A
    Scand J Rheumatol; 2003; 32(3):156-61. PubMed ID: 12892252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment.
    Skoumal M; Haberhauer G; Feyertag J; Kittl EM; Bauer K; Dunky A
    Rheumatol Int; 2006 Sep; 26(11):1001-4. PubMed ID: 16485108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis].
    Marti C; Neidhart M; Gerber T; Hauser N; Michel BA; Häuselmann HJ
    Z Rheumatol; 1999 Apr; 58(2):79-87. PubMed ID: 10408068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can tocilizumab decrease cartilage oligomeric matrix protein levels and disease activity in patients with long-standing rheumatoid arthritis?
    Benucci M; Meacci F; Manfredi M; Gobbi FL; Infantino M; Ricci C; Sarzi-Puttini P; Atzeni F
    Curr Rheumatol Rev; 2014; 10(2):131-5. PubMed ID: 25599685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis.
    Wisłowska M; Jabłońska B
    Clin Rheumatol; 2005 Jun; 24(3):278-84. PubMed ID: 15940561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic laboratory markers of joint damage in rheumatoid arthritis.
    Lindqvist E; Eberhardt K; Bendtzen K; Heinegård D; Saxne T
    Ann Rheum Dis; 2005 Feb; 64(2):196-201. PubMed ID: 15458956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cartilage oligomeric matrix protein associates differentially with erosions and synovitis and has a different temporal course in cyclic citrullinated peptide antibody (anti-CCP)-positive versus anti-CCP-negative early rheumatoid arthritis.
    Christensen AF; Lindegaard H; Hørslev-Petersen K; Hetland ML; Ejbjerg B; Stengaard-Pedersen K; Jacobsen S; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Tarp U; Pødenphant J; Østergaard M; Junker P
    J Rheumatol; 2011 Aug; 38(8):1563-8. PubMed ID: 21572145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments.
    Morozzi G; Fabbroni M; Bellisai F; Pucci G; Galeazzi M
    Ann N Y Acad Sci; 2007 Jun; 1108():398-407. PubMed ID: 17894003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evidence of cartilaginous benefit of treatment with infliximab in rheumatoid arthritis using measurement of serum COMP].
    Yamamoto M; Takahashi H; Ohara M; Suzuki C; Naishiro Y; Yamamoto H; Shinomura Y; Imai K
    Nihon Rinsho Meneki Gakkai Kaishi; 2007 Feb; 30(1):41-7. PubMed ID: 17332704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept.
    Crnkic M; Månsson B; Larsson L; Geborek P; Heinegård D; Saxne T
    Arthritis Res Ther; 2003; 5(4):R181-5. PubMed ID: 12823852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors.
    Hjeltnes G; Hollan I; Førre Ø; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    J Rheumatol; 2012 Jul; 39(7):1341-7. PubMed ID: 22660798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.
    Cuchacovich M; Catalan D; Wainstein E; Gatica H; Soto L; Aravena O; Pesce B; Sabugo F; Aguillón JC
    Clin Exp Rheumatol; 2008; 26(6):1067-73. PubMed ID: 19210871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab.
    Nakajima S; Naruto T; Miyamae T; Imagawa T; Mori M; Nishimaki S; Yokota S
    Mod Rheumatol; 2009; 19(1):42-6. PubMed ID: 18726067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT study.
    de Jong Z; Munneke M; Vilim V; Zwinderman AH; Kroon HM; Ronday HK; Lems WF; Dijkmans BA; Breedveld FC; Vliet Vlieland TP; Hazes JM; Degroot J
    Rheumatology (Oxford); 2008 Jun; 47(6):868-71. PubMed ID: 18400837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity.
    Söderlin MK; Kastbom A; Kautiainen H; Leirisalo-Repo M; Strandberg G; Skogh T
    Scand J Rheumatol; 2004; 33(3):185-8. PubMed ID: 15228190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis.
    Nikolaisen C; Rekvig OP; Nossent HC
    Scand J Rheumatol; 2007; 36(2):97-100. PubMed ID: 17476614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.